Hologic's Lorad division has received an approvable letter from the U.S. Food and Drug Administration for its Lorad Full-Field Digital Mammography system. The agency's action should be the end of a long regulatory road for Lorad, which has struggled to get the FFDM system to market.
The approvable letter applies to Lorad's FFDM premarket approval (PMA) application, filed earlier this year. The PMA was based on three years of clinical data collected at major medical institutions around the world, according to the company.
Lorad's previous corporate parent, Trex Medical, originally tried to gain approval for the product under the 510(k) process. But after two years under review, the FDA stymied that effort in 1999 by ruling that the system was not substantially equivalent to analog mammography systems and therefore had to go through the PMA process.
Hologic of Bedford, MA, said that final clearance for the product is subject to labeling discussions, a good manufacturing practices audit, and other details. Hologic is also developing a second-generation FFDM system that will use its DirectRay amorphous selenium flat-panel digital technology. This system will require a separate FDA review, Hologic said.
By AuntMinnie.com staff writersOctober 26, 2001
Related Reading
Hologic's new CEO takes aim at digital mammography, September 18, 2001
Hologic trims net loss, August 13, 2001
Hologic settles with Fleet, August 10, 2001
Hologic files PMA for Lorad digital mammography system, May 4, 2001
Hologic to use both Trex, DRC technology in digital mammo, March 2, 2001
Copyright © 2001 AuntMinnie.com











![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)






